At its Annual Meeting of Stockholders held on June 18, 2026, Eledon Pharmaceuticals, Inc. stockholders approved an amendment to the Certificate of Incorporation to increase authorized common stock from 300,000,000 to 450,000,000 shares. The meeting also resulted in the election of David-Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson as Class III Directors for three-year terms ending in 2029. Additionally, stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Eledon Pharmaceuticals is a biopharmaceutical company.